Angioplasties

Jump to

Under cost pressure, Abbott to urge NPPA to allow withdrawal of stents again

Last week, Indian drug regulator NPPA rejected applications filed by Abbott and Medtronics to withdraw their stent products from market technical grounds.
NPPA simplifies rules to ensure no stents shortage to patients

NPPA said relabelling of stents is not mandatory, and called upon manufacturers and importers to issue revised price lists as quickly as possible in line with its price cap order - a move seen as an attempt to simplify the process ensure continuation of cardiac services to patients.

Advisory Alert: It has come to our attention that certain individuals are representing themselves as affiliates of Moneycontrol and soliciting funds on the false promise of assured returns on their investments. We wish to reiterate that Moneycontrol does not solicit funds from investors and neither does it promise any assured returns. In case you are approached by anyone making such claims, please write to us at grievanceofficer@nw18.com or call on 02268882347

Angioplasties

Under cost pressure, Abbott to urge NPPA to allow withdrawal of stents again

NPPA simplifies rules to ensure no stents shortage to patients